Literature DB >> 15371923

Irritable bowel syndrome in France: a common, debilitating and costly disorder.

Michel Dapoigny1, Jérôme Bellanger, Bruno Bonaz, Stanislas Bruley des Varannes, Lionel Bueno, Benoît Coffin, Philippe Ducrotté, Bernard Flourié, Marc Lémann, Anne Lepicard, Olivier Reigneau.   

Abstract

OBJECTIVE: This epidemiological investigation aims to measure the prevalence of irritable bowel syndrome (IBS) in the general population using the Rome II criteria and to evaluate the medical management including treatments and the impact of IBS on patient life.
METHODS: A nationally representative sample of 20,000 French subjects, aged 18 years and over, were interviewed by SOFRES (French Public Opinion Poll Institute) in May 2001. In a second phase (June/July 2001), a 48-question self-administered questionnaire was given to the subjects who have been selected during the first phase as suffering from IBS (Rome II criteria).
RESULTS: The prevalence of IBS was 4.7% (confidence interval, 4.36-5.04% with 5% risk) with a predominance in women (5.7% versus 3.7%, P < 0.01). The abdominal pain was often longstanding (> 5 years, 50%), intense (43%) and nocturnal (35%). During the most recent painful episode the levels of associated transit problems were almost equally divided between diarrhoea (36%), constipation (29%) and alternate episodes of both (31%). Apart from pain, bloating was given as the most frequent (73%) and most troublesome (24%) symptom. Since the onset, 80% of subjects with IBS had consulted a doctor (90% consulted a general physician, 57% a gastroenterologist, 50% both) and of these, 80% consulted within the previous 12 months. Sixty-seven per cent of subjects underwent additional investigations since the start of their illness (average of 3.4 examinations per patient examined: colonoscopy, 34.1%; laboratory tests, 34%; and abdominal ultrasound, 27.7%). Over the previous 12 months, 8% of the subjects had been admitted to hospital (average length of stay, 6.6 days), 11% of employed subjects had to take time off, 93% of subjects had taken prescribed medication (87%), but 43% of people thought it was ineffective. The effect on daily life was considerable (score, 6.2/10; close to the score for flu, 7/10). Two-thirds of the individuals changed their diet; 54% said it affected their social life and 29% their professional life. Seventy-four per cent of patients trusted their doctor, with a satisfaction index of 63%, but 45% of patients would like to have more information on IBS.
CONCLUSION: This study confirmed that the Rome II criteria detected IBS with a prevalence of 4.7%. The recruited subjects had severe symptoms (frequency, intensity and duration) that had a considerable effect on their daily life. The high level of referrals and initial consultations in all categories and the patient's attitudes towards the illness and its treatment emphasize the relative ineffectiveness of care for patients suffering from IBS.

Entities:  

Mesh:

Year:  2004        PMID: 15371923     DOI: 10.1097/00042737-200410000-00008

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  28 in total

Review 1.  Gastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidence.

Authors:  J G Williams; S E Roberts; M F Ali; W Y Cheung; D R Cohen; G Demery; A Edwards; M Greer; M D Hellier; H A Hutchings; B Ip; M F Longo; I T Russell; H A Snooks; J C Williams
Journal:  Gut       Date:  2007-02       Impact factor: 23.059

2.  Prevalence, impact and attitudes toward lower gastrointestinal dysmotility and sensory symptoms, and their treatment in Canada: A descriptive study.

Authors:  Richard H Hunt; Surinder Dhaliwal; Gervais Tougas; Carmen Pedro; Jean-Francois Labbé; Heidi Paul; Michael Ennamorato
Journal:  Can J Gastroenterol       Date:  2007-01       Impact factor: 3.522

Review 3.  Irritable bowel syndrome.

Authors:  Antonella Spinelli
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

4.  A cost analysis of functional bowel disorders in Iran.

Authors:  Delnaz Roshandel; Mohammadreza Rezailashkajani; Sepideh Shafaee; Mohammad Reza Zali
Journal:  Int J Colorectal Dis       Date:  2006-10-25       Impact factor: 2.571

Review 5.  Probiotic use in irritable bowel syndrome.

Authors:  Patrick Young; Brooks D Cash
Journal:  Curr Gastroenterol Rep       Date:  2006-08

6.  Increased Prevalence of Irritable Bowel Syndrome in a Cohort of French Morbidly Obese Patients Candidate for Bariatric Surgery.

Authors:  Anne Sophie Schneck; Rodolphe Anty; Albert Tran; Audrey Hastier; Imed Ben Amor; Jean Gugenheim; Antonio Iannelli; Thierry Piche
Journal:  Obes Surg       Date:  2016-07       Impact factor: 4.129

7.  Predictors of Health-related Quality of Life in Irritable Bowel Syndrome Patients Compared With Healthy Individuals.

Authors:  Raymond Addante; Bruce Naliboff; Wendy Shih; Angela P Presson; Kirsten Tillisch; Emeran A Mayer; Lin Chang
Journal:  J Clin Gastroenterol       Date:  2019-04       Impact factor: 3.062

8.  The current prevalence of irritable bowel syndrome in Asia.

Authors:  Full-Young Chang; Ching-Liang Lu; Tseng-Shing Chen
Journal:  J Neurogastroenterol Motil       Date:  2010-10-30       Impact factor: 4.924

9.  Therapeutic advances in functional gastrointestinal disease: irritable bowel syndrome.

Authors:  Alexandru Gaman; Maria Cristina Bucur; Braden Kuo
Journal:  Therap Adv Gastroenterol       Date:  2009-05-01       Impact factor: 4.409

10.  Low risk of irritable bowel syndrome after Clostridium difficile infection.

Authors:  T Piche; G Vanbiervliet; F Girard Pipau; R Dainese; X Hébuterne; P Rampal; S M Collins
Journal:  Can J Gastroenterol       Date:  2007-11       Impact factor: 3.522

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.